1Harris DM,Chen X,Pesant S,et al.Inhibition of angio-tensin II Gq signaling augmentsβ-adrenergic receptor medi-ated effects in a renal artery stenosis model of high bloodpressure[J].J Mol Cell Cardiol,2009,46:100-107.
2Simkoa F, Matuskovaa J, Luptak I, et al. Effect of simvastatin onremodeling of the left ventricle and aorta in LNAME - induced hypertension[J]. Life Sci,2004,74(10) : 1211 - 1224.
3Porter KE,Turner NA, ORegan DJ, et al. Simvastatin reduces hu manatrial myofibroblast proliferation independently of cholesterol loweringVia inhibition of RhoA[ J ]. Cardiovasc Res, 2004,61 (4) : 745- 755.
4Tziakas DN, Chalikias GK, Parissis JT, et al. Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short - term atorvastatin administration[J],Int J Cardiol,2004,94(2 - 3) :269 - 277.
5Zhang GG, Zhang SD. Effect of simavastatin on cardiac fibrosis in patients with essential hypertension[ J ]. Journal of Central South University (Medical Sciences), 2005,30 (3) : 280 - 282.
6Yu Q, Stamenkovic I. Cell surface- localized matrix metallo - proteinase - 9 proteolytically activates TGF - β and promotes tumor invasion and angiogenesis[ J ]. Genes Dev, 2000,14 (2) : 163 - 176.
7Kuusisto J, Andrulionyte L, Laakso M. Atherosclerosis and cardiovascular risk reduction with PPAR agonists [ J ]. Current Atherosclerosis Reports, 2007, 9 ( 4 ) : 274 - 280.
8Keech A, Simes R J, Barter P, et al. Effects of long - term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetesmellitus ( the FIELD study) : randomized controlled trial [ J ]. Lancet, 2005, 366(9500):1849 -1861.
10Gilde A J, Van Der Lee KA, Willemsen PH, et al. PPARct and PPARβ/δ, but not PPARγ, modulate the expression of genes involved in cardiac lipid metabolism[J]. Circ Res, 2003, 92(5) :518 -524.
